"GLP-1 Diabetes Drug Shows Promise in Slowing Parkinson's Progression"
TL;DR
New data from a French academic trial published in the New England Journal of Medicine suggests the potential for treating Parkinson’s disease with a GLP-1 agonist, although the impact so far is modest and important questions remain. The study adds to the growing body of research indicating the potential of the GLP-1 drug class to treat a wide range of conditions beyond diabetes and obesity, including kidney and heart disease, sleep apnea, and depression.
Topics:healthhealth-medical-research#eli-lilly#glp-1-agonist#health-medical-research#medical-research#novo-nordisk#parkinsons-disease
- Academic trial suggests modest GLP-1 effect in Parkinson's disease, but questions remain Endpoints News
- Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial CNBC
- An Ozempic Relative Slowed Parkinson's Disease in a Small Study The New York Times
- Diabetes drug seems to slow progress of Parkinson’s in French-backed trial MarketWatch
- GLP-1 drug may help with Parkinson's disease, study reports STAT
Want the full story? Read the original reporting
Read on Endpoints News